RS53586B1 - Derivati deoksiaktagardina - Google Patents

Derivati deoksiaktagardina

Info

Publication number
RS53586B1
RS53586B1 RSP20140585A RS53586B1 RS 53586 B1 RS53586 B1 RS 53586B1 RS P20140585 A RSP20140585 A RS P20140585A RS 53586 B1 RS53586 B1 RS 53586B1
Authority
RS
Serbia
Prior art keywords
compound
compounds
preparation
treatment
deoxyactagardine
Prior art date
Application number
Other languages
English (en)
Serbian (sr)
Inventor
Sjoerd Nicolaas Wadman
Original Assignee
Novacta Biosystems Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Limited filed Critical Novacta Biosystems Limited
Publication of RS53586B1 publication Critical patent/RS53586B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
RSP20140585 2009-01-14 2010-01-12 Derivati deoksiaktagardina RS53586B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14449009P 2009-01-14 2009-01-14
PCT/GB2010/000042 WO2010082018A1 (en) 2009-01-14 2010-01-12 Deoxyactagardine derivatives

Publications (1)

Publication Number Publication Date
RS53586B1 true RS53586B1 (sr) 2015-02-27

Family

ID=42110329

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP20140585 RS53586B1 (sr) 2009-01-14 2010-01-12 Derivati deoksiaktagardina

Country Status (22)

Country Link
US (2) US8283371B2 (cg-RX-API-DMAC10.html)
EP (1) EP2387580B1 (cg-RX-API-DMAC10.html)
JP (1) JP5719312B2 (cg-RX-API-DMAC10.html)
KR (1) KR20110119699A (cg-RX-API-DMAC10.html)
CN (1) CN102348718B (cg-RX-API-DMAC10.html)
AU (1) AU2010205472B2 (cg-RX-API-DMAC10.html)
CA (1) CA2749278A1 (cg-RX-API-DMAC10.html)
DK (1) DK2387580T3 (cg-RX-API-DMAC10.html)
EA (1) EA021683B1 (cg-RX-API-DMAC10.html)
ES (1) ES2520165T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20141084T1 (cg-RX-API-DMAC10.html)
IL (1) IL213927A0 (cg-RX-API-DMAC10.html)
MX (1) MX2011007313A (cg-RX-API-DMAC10.html)
NZ (1) NZ594011A (cg-RX-API-DMAC10.html)
PL (1) PL2387580T3 (cg-RX-API-DMAC10.html)
PT (1) PT2387580E (cg-RX-API-DMAC10.html)
RS (1) RS53586B1 (cg-RX-API-DMAC10.html)
SG (1) SG172944A1 (cg-RX-API-DMAC10.html)
SI (1) SI2387580T1 (cg-RX-API-DMAC10.html)
TW (1) TWI453029B (cg-RX-API-DMAC10.html)
WO (1) WO2010082018A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201104991B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
DK2387580T3 (da) 2009-01-14 2014-10-13 Novacta Biosystems Ltd Deoxyactagardinderivater
EA020733B1 (ru) 2009-02-04 2015-01-30 Новакта Биосистемс Лимитед Производные актагардина
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013508D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201213434D0 (en) 2012-07-27 2012-09-12 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) * 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (cg-RX-API-DMAC10.html) * 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
ATE255165T1 (de) 1994-09-12 2003-12-15 Aventis Pharma Gmbh Rekombinantes mersacidin und verfahren zu seiner herstellung
US5866539A (en) 1995-06-23 1999-02-02 Ambi Inc. Method for the control of antibiotic-resistant gram positive bacteria and treatment of infection
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) * 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
EP1558746A4 (en) 2002-10-10 2006-11-22 Molichem Medicines Inc DURAMYCIN-CODING NUCLEIC ACIDS
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
ATE356143T1 (de) 2003-07-18 2007-03-15 Vicuron Pharm Inc Antibiotikum 107891, dessen faktoren a1 und a2, pharmazeutisch unbedenkliche salze und zusammensetzungen, und anwendung davon
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
EP1928900A1 (en) 2005-09-27 2008-06-11 Novacta Biosystems Limited Variants of the lantibiotic mersacidin and their use
GB0600928D0 (en) * 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
CA2667167C (en) 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
WO2008151434A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
AU2008364202A1 (en) 2008-11-24 2011-07-07 Sentinella Pharmaceuticals, Inc. ("Sentinella") Lantibiotic carboxyamide derivatives with enhanced antibacterial activity
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
DK2387580T3 (da) 2009-01-14 2014-10-13 Novacta Biosystems Ltd Deoxyactagardinderivater
EA020733B1 (ru) 2009-02-04 2015-01-30 Новакта Биосистемс Лимитед Производные актагардина

Also Published As

Publication number Publication date
JP5719312B2 (ja) 2015-05-13
IL213927A0 (en) 2011-07-31
ES2520165T3 (es) 2014-11-11
TW201029661A (en) 2010-08-16
ZA201104991B (en) 2013-10-31
CN102348718B (zh) 2015-06-03
EP2387580A1 (en) 2011-11-23
US20100179207A1 (en) 2010-07-15
HRP20141084T1 (hr) 2015-02-13
EA201190071A1 (ru) 2012-06-29
PT2387580E (pt) 2014-10-30
JP2012515195A (ja) 2012-07-05
WO2010082018A1 (en) 2010-07-22
NZ594011A (en) 2013-12-20
US20120277145A1 (en) 2012-11-01
EP2387580B1 (en) 2014-08-13
AU2010205472A1 (en) 2011-07-28
SG172944A1 (en) 2011-08-29
EA021683B1 (ru) 2015-08-31
SI2387580T1 (sl) 2014-11-28
KR20110119699A (ko) 2011-11-02
DK2387580T3 (da) 2014-10-13
MX2011007313A (es) 2011-08-04
US8741945B2 (en) 2014-06-03
CN102348718A (zh) 2012-02-08
AU2010205472B2 (en) 2013-03-14
CA2749278A1 (en) 2010-07-22
US8283371B2 (en) 2012-10-09
TWI453029B (zh) 2014-09-21
PL2387580T3 (pl) 2015-01-30

Similar Documents

Publication Publication Date Title
JP5719312B2 (ja) デオキシアクタガルジン誘導体
TWI504610B (zh) 阿肽加定衍生物、其製備方法及其用途
US20230090435A1 (en) Compounds with Antimicrobial Properties
WO2010082019A1 (en) Actagardine derivatives, and pharmaceutical use thereof
US12187754B2 (en) LpxC inhibitors and uses thereof
CN108239123A (zh) 吡喃葡萄糖基衍生物的共晶、制备方法和应用
WO2022088091A1 (zh) 补骨脂酚衍生物、其药学上可接受的盐及其制备方法和应用
CN116082430B (zh) 一种具有抗菌活性的别胆酸衍生物及其药用组合物
CA3173812C (en) Systemic formulation of a pyridinone derivate for coeliac disease
JP7334183B2 (ja) グリコシルトランスフェラーゼ阻害剤
WO2012020220A1 (en) Compounds
CN104860896B (zh) 茚酮内盐衍生物及其晶型和它们的制备方法与用途
HK40070529A (en) Systemic formulation of a pyridinone derivate for coeliac disease
WO2012020221A1 (en) Compounds
WO2012020222A1 (en) Compounds
FR2941956A1 (fr) NOUVELLES MOLECULES HYBRIDES VANCOMYCINE-AMINOQUINOLEINE DENOMMEES "VANCOMYQUINESr", LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE